EP2621931A4 - TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION - Google Patents
TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONInfo
- Publication number
- EP2621931A4 EP2621931A4 EP11827912.4A EP11827912A EP2621931A4 EP 2621931 A4 EP2621931 A4 EP 2621931A4 EP 11827912 A EP11827912 A EP 11827912A EP 2621931 A4 EP2621931 A4 EP 2621931A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- indolate
- tetracyclic
- hepatitis
- derivatives
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/077493 WO2012040923A1 (en) | 2010-09-29 | 2010-09-29 | Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases |
| US201061426724P | 2010-12-23 | 2010-12-23 | |
| PCT/CN2011/001638 WO2012041014A1 (en) | 2010-09-29 | 2011-09-28 | Tetracyclic indole derivatives for treating hepatitis c virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2621931A1 EP2621931A1 (en) | 2013-08-07 |
| EP2621931A4 true EP2621931A4 (en) | 2014-03-19 |
Family
ID=45891857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11827912.4A Withdrawn EP2621931A4 (en) | 2010-09-29 | 2011-09-28 | TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2621931A4 (en) |
| JP (1) | JP2013538831A (en) |
| KR (1) | KR20140001879A (en) |
| AU (1) | AU2011307953B2 (en) |
| BR (1) | BR112013007696A2 (en) |
| CA (1) | CA2811662A1 (en) |
| MX (1) | MX2013003631A (en) |
| WO (1) | WO2012041014A1 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| RS56654B8 (en) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| EA020031B1 (en) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Anti-viral compounds |
| EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
| MX2012010918A (en) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections. |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| EP2616461A4 (en) | 2010-08-26 | 2014-03-26 | Rfs Pharma Llc | POWERFUL AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2841095A1 (en) | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| SI2709613T2 (en) | 2011-09-16 | 2020-12-31 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Methods for treating hcv |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| IN2014MN01547A (en) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| TWI610916B (en) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof |
| WO2014082380A1 (en) | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| TWI585082B (en) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof |
| WO2014110688A1 (en) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2014110687A1 (en) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| NZ729172A (en) | 2013-01-31 | 2018-06-29 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| WO2014121418A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121417A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN111116563B (en) * | 2013-06-06 | 2023-07-04 | 上海爱博医药科技有限公司 | Compound for inhibiting hepatitis C virus, pharmaceutical composition and application thereof |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105530933B (en) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | For treating the combination product comprising biphenyl derivatives of HCV |
| JP2016529293A (en) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | Combination preparation of two antiviral compounds |
| WO2015065821A1 (en) * | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Process for preparing tetracyclic heterocycle compounds |
| WO2015089810A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US9738629B2 (en) | 2014-01-23 | 2017-08-22 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
| WO2016004899A1 (en) | 2014-07-11 | 2016-01-14 | Merck Sharp & Dohme Corp. | Process for making tetracyclic heterocycle compounds |
| US10457690B2 (en) | 2015-06-04 | 2019-10-29 | Merck Sharp & Dohme Corp. | Process for preparing substituted tetracyclic heterocycle compounds |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN108290904B (en) * | 2015-12-10 | 2020-10-09 | 正大天晴药业集团股份有限公司 | Deuterium-modified elbasvir derivatives, pharmaceutical compositions containing the compounds and uses thereof |
| WO2017181947A1 (en) * | 2016-04-20 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | Substituted diamine carbamate, and pharmaceutical composition and application thereof |
| EP3473639B1 (en) * | 2016-06-21 | 2023-03-29 | Zhejiang Palo Alto Pharmaceuticals, Inc | Hepatitis c virus inhibitor and application |
| WO2018032468A1 (en) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| WO2018032467A1 (en) | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases |
| RU2650610C1 (en) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Antiviral composition and method of its application |
| RU2659388C1 (en) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application |
| CA3219397A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| JP7725617B2 (en) | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | Pentacyclic derivatives as Zika virus inhibitors |
| BR112023026356A2 (en) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | METHOD FOR TREATING HEPATITIS C VIRUS OR A CONDITION RESULTING FROM A HEPATITIS C INFECTION, COMBINATION, USE OF THE COMBINATION, PHARMACEUTICAL COMPOSITION, AND, KIT FOR TREATMENT OF HEPATITIS C VIRUS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US20080299075A1 (en) * | 2006-08-11 | 2008-12-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2010111483A1 (en) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BRPI0922366B8 (en) * | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | compound, pharmaceutical composition and use of a compound |
| EP2774927A1 (en) * | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
-
2011
- 2011-09-28 BR BR112013007696A patent/BR112013007696A2/en not_active IP Right Cessation
- 2011-09-28 KR KR1020137010717A patent/KR20140001879A/en not_active Withdrawn
- 2011-09-28 JP JP2013530529A patent/JP2013538831A/en not_active Withdrawn
- 2011-09-28 AU AU2011307953A patent/AU2011307953B2/en not_active Expired - Fee Related
- 2011-09-28 WO PCT/CN2011/001638 patent/WO2012041014A1/en not_active Ceased
- 2011-09-28 MX MX2013003631A patent/MX2013003631A/en not_active Application Discontinuation
- 2011-09-28 EP EP11827912.4A patent/EP2621931A4/en not_active Withdrawn
- 2011-09-28 CA CA2811662A patent/CA2811662A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US20080299075A1 (en) * | 2006-08-11 | 2008-12-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2010111483A1 (en) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2012041014A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013007696A2 (en) | 2019-09-24 |
| JP2013538831A (en) | 2013-10-17 |
| AU2011307953B2 (en) | 2014-07-31 |
| EP2621931A1 (en) | 2013-08-07 |
| AU2011307953A1 (en) | 2013-04-04 |
| WO2012041014A1 (en) | 2012-04-05 |
| KR20140001879A (en) | 2014-01-07 |
| CA2811662A1 (en) | 2012-04-05 |
| MX2013003631A (en) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2621932A4 (en) | TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | |
| EP2658857A4 (en) | SUBSTITUTED PURIC NUCLEOSIDES, DERIVATIVES PHOSPHORAMIDATE AND PHOSPHORODIAMIDATE FOR THE TREATMENT OF VIRAL INFECTIONS | |
| MA37712B1 (en) | Macrocyclic inhibitors of flaviviridae virus | |
| EP2744332A4 (en) | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | |
| EP2753618A4 (en) | HETEROCYCLE-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES | |
| EA201290053A1 (en) | FLAVIVIRIDAE VIRUS INHIBITORS | |
| EP2503881A4 (en) | FUSED TRICYCLIC COMPOUNDS AND THEIR DERIVATIVES USEFUL FOR THE TREATMENT OF VIRAL DISEASES | |
| EP2385951A4 (en) | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| EP2475254A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| EP2552203A4 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| IN2014MN02652A (en) | ||
| EP2752198A4 (en) | PREPARATION OF VACCINE FOR THE TREATMENT OF CANCER | |
| EP2152261A4 (en) | TREATMENT OF INJURIES CAUSED BY VIRUSES | |
| EP2633051A4 (en) | TREATMENT OF HBV INFECTION | |
| EP2888240A4 (en) | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | |
| IN2012DN01855A (en) | ||
| EP2726066A4 (en) | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME | |
| EP2782578A4 (en) | METHOD FOR TREATING HEPATITIS C VIRUS INFECTION USING QUERCETIN-CONTAINING COMPOSITIONS | |
| EP2646043A4 (en) | NEW CICLOSPORINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | |
| MA29097B1 (en) | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS BY FLAVIVIRIDAE | |
| EP2875024A4 (en) | AMIDO-SUBSTITUTED PYRIMIDINONE DERIVATIVES FOR USE IN THE TREATMENT OF HIV INFECTION | |
| EP2506712A4 (en) | MORPHINANE DERIVATIVES FOR THE TREATMENT OF DRUG OVERDOSE | |
| BR112013007696A2 (en) | compound, pharmaceutical composition, uses of said compound and said composition | |
| EP2341924A4 (en) | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | |
| EP2816054A4 (en) | MACROCYCLIC COMPOUNDS FOR SUPPRESSING THE REPLICATION OF HEPATITIS C VIRUS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130429 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20140213 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 31/12 20060101ALN20140207BHEP Ipc: C07D 487/04 20060101ALI20140207BHEP Ipc: C07D 471/04 20060101ALI20140207BHEP Ipc: C07D 498/04 20060101AFI20140207BHEP Ipc: A61K 31/5365 20060101ALI20140207BHEP Ipc: A61K 31/4985 20060101ALI20140207BHEP Ipc: A61K 31/437 20060101ALI20140207BHEP Ipc: A61P 31/14 20060101ALI20140207BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20150126 |